Skip to main content
Clinical Trials/NCT06613529
NCT06613529
Completed
N/A

Effectiveness of Online Mindfulness Platform in Improving Anxiety, Depression, and Stress in Adults During the COVID-19 Pandemic: a Randomized Control Trial

Taipei Medical University1 site in 1 country60 target enrollmentNovember 9, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
COVID-19 Pandemic
Sponsor
Taipei Medical University
Enrollment
60
Locations
1
Primary Endpoint
Assessment of anxiety
Status
Completed
Last Updated
last year

Overview

Brief Summary

During the COVID-19 pandemic, adults may experience emotional stress and impact. To reduce the risk of cross-infection, this study aims to use online mindfulness training to improve emotional well-being during the pandemic and assess their effectiveness.

Detailed Description

he COVID-19 pandemic had a detrimental global impact on the health of most populations. It causes and also generates further damage to physiology and psychology. Mindfulness is recognized as an effective method for improving the symptoms of physical and mental problems. The purpose of this review will explore the efficacy of an online mindfulness intervention for individuals or groups that impacted symptoms of physiology and psychology in adults during the pandemic base on the principle of evidence-based medicine. At the same time, a set of mindfulness intervention plans will be developed based on the best evidence searched, and a pilot study will be conducted. Therefore, this research design will be divided into two stages. In the first stage, six electronic bibliographic databases will be comprehensively searched for randomized controlled trials that have been published from February 2020 to currently published articles. The research subjects are adults who live in the community and accept online mindfulness intervention. Quality assessment will be performed according to the Cochrane Collaboration's Risk of Bias tool will be used for randomized controlled clinical trials (RCTs). A meta-analysis of the intervention timing and measurements will be performed using Review Manager 5.1 software. The second phase will be a randomized controlled trial pilot study of mindfulness interventions, The research subjects will be divided into two groups, namely the mindfulness intervention experimental group (E) and the control group (C). The researcher uses structured questionnaires to collect data before intervention (To) and at 4 weeks (T1), 8 weeks (T2) after the intervention. Data will be analyzed using the Generalized Estimating Equation to analyze the repeated measurements and intention-to-treat analysis for reducing attrition bias.

Registry
clinicaltrials.gov
Start Date
November 9, 2022
End Date
March 8, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients over 20 years of age
  • Conscious
  • Able to communicate in Taiwanese

Exclusion Criteria

  • Patients currently receiving antidepressant or anti-anxiety medications
  • Patients unable to communicate verbally
  • Patients who refuse to provide informed consent

Outcomes

Primary Outcomes

Assessment of anxiety

Time Frame: Anxiety was assessed before the intervention, and at 4 and 8 weeks after the intervention.

Anxiety levels were assessed using the odd-numbered questions of the Hospital Anxiety and Depression Scale (HADS-14). The full title of HADS-14 is Hospital Anxiety and Depression Scale. This scale consists of 14 items, with 7 items specifically measuring anxiety, known as the Anxiety Subscale (HADS-A). Each item in the Anxiety Subscale is rated on a 4-point Likert scale, ranging from 0 (no symptoms) to 3 (significant symptoms). The total score for the anxiety subscale can range from 0 to 21. Higher scores indicate worse outcomes, specifically reflecting greater levels of anxiety. The scoring is categorized as follows: * 0-7: Normal anxiety levels * 8-10: Borderline abnormal anxiety (suggesting possible anxiety) * 11-21: Abnormal anxiety (indicating clinical levels of anxiety)

Secondary Outcomes

  • Assessment of depression(Depression was assessed before the intervention, and at 4 and 8 weeks after the intervention.)

Study Sites (1)

Loading locations...

Similar Trials